Caris Life Sciences, Inc. Common Stock Asset Resilience Ratio
Caris Life Sciences, Inc. Common Stock asset resilience ratio. Caris Life Sciences, Inc. Common Stock (CAI) has an Asset Resilience Ratio of 8.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Caris Life Sciences, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Caris Life Sciences, Inc. Common Stock (2009–2025)
Asset resilience ratio of Caris Life Sciences, Inc. Common Stock from 2009 to 2025. This chart shows how Caris Life Sciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read CAI liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Caris Life Sciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Caris Life Sciences, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $102.20 Million | 8.31% |
| Total Liquid Assets | $102.20 Million | 8.31% |
Asset Resilience Insights
- Limited Liquidity: Caris Life Sciences, Inc. Common Stock maintains only 8.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Caris Life Sciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Caris Life Sciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Caris Life Sciences, Inc. Common Stock Asset Resilience Ratio by Year (2009–2025)
Caris Life Sciences, Inc. Common Stock asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Caris Life Sciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.20% | $2.29 Million | $1.13 Billion | -0.44pp |
| 2024-12-31 | 0.64% | $2.20 Million | $343.73 Million | -15.15pp |
| 2023-12-31 | 15.79% | $65.18 Million | $412.90 Million | -26.37pp |
| 2022-12-31 | 42.16% | $302.43 Million | $717.42 Million | +39.13pp |
| 2020-12-31 | 3.02% | $78.99 Million | $2.61 Billion | +0.50pp |
| 2018-12-31 | 2.52% | $75.97 Million | $3.01 Billion | +1.28pp |
| 2017-12-31 | 1.24% | $30.06 Million | $2.43 Billion | +0.27pp |
| 2016-12-31 | 0.97% | $19.96 Million | $2.06 Billion | -0.09pp |
| 2015-12-31 | 1.07% | $21.16 Million | $1.99 Billion | +0.05pp |
| 2014-12-31 | 1.01% | $18.15 Million | $1.80 Billion | +0.23pp |
| 2013-12-31 | 0.78% | $13.00 Million | $1.68 Billion | +0.01pp |
| 2012-12-31 | 0.77% | $10.62 Million | $1.39 Billion | +0.12pp |
| 2011-12-31 | 0.65% | $6.16 Million | $953.37 Million | +0.00pp |
| 2010-12-31 | 0.64% | $3.95 Million | $613.45 Million | -1.17pp |
| 2009-12-31 | 1.81% | $6.78 Million | $374.08 Million | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more